Stock Price Quote

GUFIC BIOSCIENCES LTD.

NSE : GUFICBIOBSE : 509079ISIN CODE : INE742B01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE364.80-19.35 (-5.04 %)
PREV CLOSE ( ) 384.15
OPEN PRICE ( ) 380.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6386
TODAY'S LOW / HIGH ( )356.95 383.70
52 WK LOW / HIGH ( )278 501.1
NSE363.75-20.75 (-5.4 %)
PREV CLOSE( ) 384.50
OPEN PRICE ( ) 383.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 363.75 (1000)
VOLUME 110430
TODAY'S LOW / HIGH( ) 357.10 387.85
52 WK LOW / HIGH ( )278 504.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-07 1984
Management Info
Jayesh P Choksi - Chairman Jayesh P Choksi - Managing Director
Registered Office

Address Shop - 37, First Floor, Kamala Bhavan I I,Swami Nityanand Road,Andheri (East),
Mumbai,
Maharashtra-400069

Phone

Email info@guficbio.com

Website www.guficbio.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

21Feb Gufic Biosciences informs about transc
In continuation to intimation dated February 17, 2025 on Earnings Confer..
12Feb Gufic Biosciences informs about confer
Pursuant to Regulation 30 read with Part A of Schedule III of the Securi..
14Jan Gufic Biosciences makes investment in
Gufic Biosciences has made an investment of AED 200,000 in Veira Life FZ..
09Aug Gufic Biosciences informs about confer
Gufic Biosciences has informed that the Company will host an Earnings Co..
06Aug Gufic Biosciences informs about analys
Pursuant to the provisions of Regulation 30 read with Part A of Schedule..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit193.25861.35
Gross Profit 262.8 1156.71
Operating Profit 358.071480.48
Net Sales 2077.948066.66

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

TTK Healthcare (BSE)
peergroup  1233.80 (0.44%)
M.Cap ( in Cr)1743.40
Jagsonpal Pharma (BSE)
peergroup  243.55 (1.82%)
M.Cap ( in Cr)1618.11
Alivus Life Sciences (BSE)
peergroup  1034.35 (0.39%)
M.Cap ( in Cr)12688.71
Oxygenta Pharma (BSE)
peergroup  85.05 (4.70%)
M.Cap ( in Cr)314.36
Bafna Pharma (BSE)
peergroup  79.74 (4.99%)
M.Cap ( in Cr)188.64

Shareholding Pattern

PROMOTERS 72.51%
MUTUAL FUNDS/UTI 3.39%
NON-INSTITUTION 23.79%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Gufic Biosciences Ltd.

Gufic Biosciences Ltd. was incorporated in the year 1984. Its today's share price is 364.8. Its current market capitalisation stands at Rs 3658.12 Cr. In the latest quarter, company has reported Gross Sales of Rs. 9401.63 Cr and Total Income of Rs.8088.43 Cr. The company's management includes Rabi N Sahoo, Shrirang V Vaidya, Anu S Aurora, Dilip B Ghosh, Pankaj J Gandhi, Pranav J Choksi, Jayesh P Choksi, Jayesh P Choksi, Ami Shah.

It is listed on the BSE with a BSE Code of 509079 , NSE with an NSE Symbol of GUFICBIO and ISIN of INE742B01025. It's Registered office is at Shop - 37, First Floor, Kamala Bhavan I I,Swami Nityanand Road,Andheri (East)Mumbai-400069, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Mayur Chokshi & Co, Mittal Agarwal & Co, SHR & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.